指南与共识糖尿病肥胖与代谢综合征

EASL-EASD-EASO 关于代谢功能障碍相关脂肪性肝病(MASLD)管理的临床实践指南:执行摘要

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
指南 / 共识 · Diabetologia · 2024-01-01

该联合指南更新了代谢功能障碍相关脂肪性肝病(MASLD)的定义、预防、筛查、诊断和治疗。建议对具有心血管代谢危险因素者采用无创检查进行纤维化病例筛查,采用血液评分(如FIB-4)序贯影像学(如瞬时弹性成像)的分步策略排除/确认进展性纤维化。推荐生活方式干预和合并症优化管理;非肝硬化MASH且显著纤维化(≥2期)者可考虑resmetirom治疗;肝硬化期目前无可推荐的MASH靶向药物。

要点

  • MASLD定义为存在一种以上心血管代谢危险因素且无有害饮酒的脂肪性肝病。
  • 具有心血管代谢危险因素、肝酶异常和/或影像学脂肪肝征象者应进行纤维化病例筛查。
  • 采用FIB-4等血液评分序贯瞬时弹性成像的分步策略排除/确认进展性纤维化。

核心结论

  • 该联合指南提供了MASLD定义、预防、筛查、诊断和治疗的更新。
  • 建议对具有心血管代谢危险因素者采用无创检查进行纤维化病例筛查。
  • 推荐生活方式干预和合并症优化管理,非肝硬化MASH伴显著纤维化(≥2期)者可考虑resmetirom治疗。
  • 肝硬化期目前无可推荐的MASH靶向药物治疗。

研究设计与样本

  • 由EASL、EASD和EASO联合制定的临床实践指南执行摘要。

关键数值与推荐

  • MASLD定义为存在一种以上心血管代谢危险因素且无有害饮酒的脂肪性肝病。
  • MASLD谱包括脂肪变、代谢功能障碍相关脂肪性肝炎(MASH)、纤维化、肝硬化和MASH相关肝细胞癌(HCC)。
  • 采用血液评分(如FIB-4)序贯影像学(如瞬时弹性成像)的分步策略适用于排除/确认进展性纤维化。
  • 非肝硬化MASH且显著纤维化(≥2期)的成人,若当地批准且取决于标签,应考虑resmetirom进行MASH靶向治疗。
  • 肝硬化期目前无可推荐的MASH靶向药物治疗。

临床怎么用

  • 具有心血管代谢危险因素、肝酶异常和/或影像学脂肪肝征象者,尤其是2型糖尿病或肥胖伴额外代谢危险因素者,应进行纤维化病例筛查。
  • 推荐生活方式干预,包括减重、饮食改变、体育锻炼和反对饮酒。
  • 推荐优化合并症管理,包括在有指征时对2型糖尿病或肥胖使用肠促胰岛素类药物(如司美格鲁肽、替尔泊肽)。
  • 肥胖的MASLD患者可选择减重手术。
  • MASH相关肝硬化的管理包括代谢药物调整、营养咨询、门静脉高压和HCC监测,以及失代偿期肝硬化行肝移植。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake. The spectrum of MASLD includes steatosis, metabolic dysfunction-associated steatohepatitis (MASH, previously NASH), fibrosis, cirrhosis and MASH-related hepatocellular carcinoma (HCC). This joint EASL-EASD-EASO guideline provides an update on definitions, prevention, screening, diagnosis and treatment for MASLD. Case-finding strategies for MASLD with liver fibrosis, using non-invasive tests, should be applied in individuals with cardiometabolic risk factors, abnormal liver enzymes and/or radiological signs of hepatic steatosis, particularly in the presence of type 2 diabetes or obesity with additional metabolic risk factor(s). A stepwise approach using blood-based scores (such as the fibrosis-4 index [FIB-4]) and, sequentially, imaging techniques (such as transient elastography) is suitable to rule-out/in advanced fibrosis, which is predictive of liver-related outcomes. In adults with MASLD, lifestyle modification-including weight loss, dietary changes, physical exercise and discouraging alcohol consumption-as well as optimal management of comorbidities-including use of incretin-based therapies (e.g. semaglutide, tirzepatide) for type 2 diabetes or obesity, if indicated-is advised. Bariatric surgery is also an option in individuals with MASLD and obesity. If locally approved and dependent on the label, adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2) should be considered for a MASH-targeted treatment with resmetirom, which demonstrated histological effectiveness on steatohepatitis and fibrosis with an acceptable safety and tolerability profile. No MASH-targeted pharmacotherapy can currently be recommended for the cirrhotic stage. Management of MASH-related cirrhosis includes adaptations of metabolic drugs, nutritional counselling, surveillance for portal hypertension and HCC, as well as liver transplantation in decompensated cirrhosis.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024. PMID: 38869512. doi:10.1007/s00125-024-06196-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。